secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000914475-22-000055
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q3 2022: INGREZZA sales $376M, GAAP EPS $0.69; raises FY guidance
----------------------------------------------------------------------------

- Q3 INGREZZA net product sales $376M (+31% YoY); TRx ~68,600 (+32% YoY).
- GAAP net income $68.5M ($0.69 diluted EPS); non-GAAP net income $106.7M ($1.08 EPS).
- Total revenue $387.9M, up 31% from $296.0M in Q3 2021.
- Raised 2022 INGREZZA sales guidance to $1.400-$1.425B; R&D & SG&A guidance reaffirmed.
- Acquired Diurnal Group plc for ~£48.3M (~$56M); sNDA for valbenazine in Huntington chorea submitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/nbix-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000914475-22-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer